AQR Capital Management
EWTX icon

AQR Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

AQR Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Buy
18,456
+9,917
+116% +$342K ﹤0.01% 3172
2026
Q1 		$269K Sell
8,539
-5,207
-38% -$150K ﹤0.01% 3460
2025
Q4 		$341K Buy
+13,746
New +$276K ﹤0.01% 3116
2025
Q2 		– Sell
-9,419
Closed -$207K – 3318
2025
Q1 		$207K Buy
9,419
+53
+0.6% +$1.39K ﹤0.01% 2869
2024
Q4 		$250K Buy
9,366
+420
+5% +$13.4K ﹤0.01% 2579
2024
Q3 		$239K Buy
+8,946
New +$178K ﹤0.01% 2493

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management's EWTX Position: Q2 2026 in Review

AQR Capital Management increased its Edgewise Therapeutics (EWTX) stake by 116% in Q2 2026, buying an estimated $342K and bringing the position to 18,456 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #3172.

AQR Capital Management first reported a position in EWTX in Q3 2024 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • AQR Capital Management held 18,456 shares of Edgewise Therapeutics worth $750K as of Q2 2026.
  • AQR Capital Management bought 9,917 Edgewise Therapeutics shares in Q2 2026, an estimated $342K.
  • Edgewise Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3172 holding.
  • AQR Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.